The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
- Investigator
- Ali Ataya
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All
Research at a glance
Top areas of exploration
- Dyspnea , 10 publications
- Pulmonary Embolism , 4 publications
- Lung Diseases , 4 publications
- Pleural Effusion , 4 publications
Research activity
Active clinical trials
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive…
- Investigator
- Ali Ataya
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Investigator
- Ali Ataya
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
103 publications
2023
Postpartum Chylothorax: A Case Report and Review of the Literature.
Cureus
PubMed • Publisher's site2023
Pulmonary hypertension in hereditary hemorrhagic telangiectasia: A clinical review
Pulmonary Circulation
PubMed • Publisher's site2023
Systemic capillary leak syndrome secondary to decompression sickness.
BMJ case reports
PubMed • Publisher's site2022
A 26-Year-Old Woman With Retinal Telangiectasias, Onychodystrophy, and Persistent Dyspnea
Chest
Publisher's site2022
A 31-Year-Old Man With Asthma, Chest Discomfort, and Shortness of Breath.
Chest
PubMed • Publisher's site